Literature DB >> 15790534

Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.

Mika Shimoji1, Li Zhang, Allen S Mandir, Valina L Dawson, Ted M Dawson.   

Abstract

Formation of alpha-synuclein aggregation and Lewy bodies (LBs) are hallmarks of Parkinson's disease (PD) and other related diseases. The dopaminergic neurotoxin, MPTP, replicates many of the pathological signs and motoric features of PD in primates and rodents by selective destruction of dopamine (DA) neurons of the substantia nigra. In this study, groups of adult wild-type C57BL6 mice were treated with MPTP either acutely (20 mg/kg, every 2 h x 4 for 1 day), semi-chronically (30 mg/kg/day for 5 days), or chronically (25 mg/kg MPTP with 250 mg/kg probenecid 2 times/week for 5 weeks). Mice brains were collected and processed at various time points for immunohistochemistry and HPLC assays. Our data showed that although there is a significant decrease in DA content and its metabolites and tyrosine hydroxylase immunoreactivity, there is no inclusion body formation following the various MPTP treatment regimens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15790534     DOI: 10.1016/j.molbrainres.2005.01.012

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  25 in total

1.  Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons.

Authors:  Italo Mocchetti; Alessia Bachis; Rachel L Nosheny; Gianluigi Tanda
Journal:  Neurotox Res       Date:  2007-09       Impact factor: 3.911

Review 2.  On the key role played by altered protein conformation in Parkinson's disease.

Authors:  L F Agnati; E Baldelli; N Andreoli; A S Woods; V Vellani; D Marcellino; D Guidolin; K Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2008-06-05       Impact factor: 3.575

Review 3.  Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol.

Authors:  Gloria E Meredith; Susan Totterdell; Judith A Potashkin; D James Surmeier
Journal:  Parkinsonism Relat Disord       Date:  2008-06-27       Impact factor: 4.891

Review 4.  MPTP mouse models of Parkinson's disease: an update.

Authors:  Gloria E Meredith; David J Rademacher
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

Review 5.  α-Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome.

Authors:  Rui Wang; Hongyang Sun; Haigang Ren; Guanghui Wang
Journal:  Sci China Life Sci       Date:  2020-07-15       Impact factor: 6.038

Review 6.  Reverse engineering Lewy bodies: how far have we come and how far can we go?

Authors:  Mohamed Bilal Fares; Somanath Jagannath; Hilal A Lashuel
Journal:  Nat Rev Neurosci       Date:  2021-01-11       Impact factor: 34.870

7.  The endoplasmic reticulum stress sensor, ATF6α, protects against neurotoxin-induced dopaminergic neuronal death.

Authors:  Naohiro Egawa; Keisuke Yamamoto; Haruhisa Inoue; Rie Hikawa; Katsunori Nishi; Kazutoshi Mori; Ryosuke Takahashi
Journal:  J Biol Chem       Date:  2010-12-03       Impact factor: 5.157

Review 8.  Neurotoxin-Induced Rodent Models of Parkinson's Disease: Benefits and Drawbacks.

Authors:  Mohamed El-Gamal; Mohamed Salama; Lyndsey E Collins-Praino; Irina Baetu; Ahmed M Fathalla; Amira M Soliman; Wael Mohamed; Ahmed A Moustafa
Journal:  Neurotox Res       Date:  2021-03-25       Impact factor: 3.911

9.  Cerebral bioimaging of Cu, Fe, Zn, and Mn in the MPTP mouse model of Parkinson's disease using laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS).

Authors:  Andreas Matusch; Candan Depboylu; Christoph Palm; Bei Wu; Günter U Höglinger; Martin K-H Schäfer; J Sabine Becker
Journal:  J Am Soc Mass Spectrom       Date:  2009-10-06       Impact factor: 3.109

10.  Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys.

Authors:  Alison L McCormack; Sally K Mak; Maryam Shenasa; William J Langston; Lysia S Forno; Donato A Di Monte
Journal:  J Neuropathol Exp Neurol       Date:  2008-08       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.